The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
News Medical on MSN8d
High discontinuation rates of GLP-1 agonists found among patients with obesityDiscontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
Recombinant mouse leptin (Dr. Parlow, National Hormone & Peptide Program, National Institute of Diabetes and Digestive and Kidney Diseases) was dissolved in 0.01 mol/l NaOH. In the first study ...
The fireside chat will be webcasted and available under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com. A replay of the webcast will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback